Clinical Trials Directory

Trials / Completed

CompletedNCT03121287

Early Imaging Biomarkers in NSCLC

Early Imaging Biomarkers to Predict Radiation-Induced Cardiopulmonary Toxicity in Patients With Thoracic Malignancies

Status
Completed
Phase
Study type
Observational
Enrollment
23 (actual)
Sponsor
University of Michigan Rogel Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate if cardiac MRI, blood biomarkers, and lung CT scans can detect early changes to the associated with radiation therapy in patients receiving radiation treatment for thoracic cancer.

Detailed description

This study seeks to investigate the utility of novel imaging biomarkers, namely whole lung volumetric CT scans and cardiac MRI, to non-invasively identify early pathologic changes in pulmonary and cardiac function resulting from thoracic radiation. The ability to identify these changes during the course of treatment offers a powerful tool to optimize radiation dose distributions within uninvolved normal tissue by adapting treatment to the individual patient response. In addition it may lead to other therapeutic interventions designed to reduce long term cardiopulmonary toxicity. The cardiac MRI will be performed using Aminophylline, Gadopentetate Dimeglumine and Regadenoson. These are not FDA approved for this purpose, but are being used off label and are IND exempt. Additionally, patients will be consented with an optional choice to retain research blood samples for 15 years after the completion of the study. This will allow cutting edge analysis for biomarkers that may be discovered in the future.

Conditions

Interventions

TypeNameDescription
OTHERImaging BiomarkersWhole lung volumetric CT scans
OTHERPulmonaryPulmonary Function Tests \& 6 minute hall walk
OTHERImagingCardiac MRI
OTHERSpecimen CollectionBlood draw

Timeline

Start date
2015-09-23
Primary completion
2019-01-01
Completion
2019-01-01
First posted
2017-04-20
Last updated
2019-08-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03121287. Inclusion in this directory is not an endorsement.